PAR-2 monoclonal antibody as a treatment for migraine: a systematic review
Abstract
Background: Migraine is a highly debilitating pathology capable of causing loss of ability to work and social life. Despite the recent introduction of monoclonal antibodies targeting the calcitonin gene-related peptide for migraine treatment, not all patients respond well to these drugs. Recently, a new class of drugs, the protease-activated receptor 2 (PAR-2) monoclonal antibodies, has emerged as a potential alternative treatment. PAR-2 is based on blocking meningeal nociceptors, which represents a new therapeutic target. Objective: To evaluate advances in migraine treatment using monoclonal antibodies targeting PAR-2. Methods: This systematic review analyzed studies from Pubmed, Lilacs, BVS, Embase, and Scielo databases, published between 2018 and 2024. The descriptors used were “monoclonal antibodies, migraine disorders, and PAR-2 receptor”, using Boolean operators "and" and "or". Systematic reviews, in vitro studies and animal studies on PAR-2 monoclonal antibodies were included. Studies that did not address its use for migraine were excluded. Two authors independently assessed the methodological quality of the studies. Results: A total of 314 articles were found, of which 15 were duplicates. 8 articles were eligible for full reading. Among the articles analyzed, a phase 1 study of MEDI0618, a PAR-2 monoclonal antibody, aimed to evaluate its safety and tolerability in healthy volunteers. Initial findings showed it was well-tolerated with no serious adverse effects;…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.